-
Vertex Pharma Calls For Redemption Of $400 Mln In Convertible Senior Subordinated Notes Due 2015
5/17/2013
|
|
|
-
Barclays Capital Is Cutting Vertex Pharmaceuticals Inc. (VRTX) FY14 Estimate To -1.17 From -1.13
5/1/2013
|
-
Barclays Capital Is Lowering Vertex Pharmaceuticals Inc. (VRTX) FY13 Estimate To -0.40 From -0.33
5/1/2013
|
-
RBC Capital Markets Is Increasing Vertex Pharmaceuticals Inc. (VRTX) 4Q13 Estimate To -0.29 From -0.31
5/1/2013
|
-
RBC Capital Markets Is Increasing Vertex Pharmaceuticals Inc. (VRTX) 3Q13 Estimate To -0.19 From -0.27
5/1/2013
|
-
RBC Capital Markets Is Increasing Vertex Pharmaceuticals Inc. (VRTX) 2Q13 Estimate To -0.15 From -0.20
5/1/2013
|
-
RBC Capital Markets Is Lowering Vertex Pharmaceuticals Inc. (VRTX) FY14 Estimate To -1.14 From -0.65
5/1/2013
|
-
RBC Capital Markets Is Cutting Vertex Pharmaceuticals Inc. (VRTX) FY13 Estimate To -2.06 From -1.00
5/1/2013
|
-
RBC Capital Markets Is Raising Vertex Pharmaceuticals Inc. (VRTX) 4Q13 Rev. Estimate To 269.1 M From 268.2 M
5/1/2013
|